Navigation Links
Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
Date:2/5/2008

onal Technidyne Corporation (ITC) Division increased 5 percent vs. the same period a year ago, with particular growth internationally and from our ProTime(R) System used in physicians' offices or patients' homes to monitor anticoagulation therapy," said Gary F. Burbach, president and chief executive officer of Thoratec.

"Clearly, the highlight of the quarter was the unanimous recommendation by the FDA Circulatory System Devices Advisory Panel on November 30 that the agency approve, with conditions, our PMA (PreMarket Approval) allowing the use of our HeartMate II for Bridge to Transplant," Burbach noted.

"It was the panel's view that the trial data demonstrated the safety and efficacy of the device, and we believe that the conditions outlined in their recommendations will not limit our ability to increase adoption of the HeartMate II. We have been engaged in a productive process with the FDA since then, and by the end of the week we expect to have submitted all the information the FDA has requested with respect to labeling, the development of an appropriate post-approval study and updates to patient data, and believe we are on track for approval and launch at the end of this quarter," he continued.

As of January 25, 2008, enrollment in the Destination Therapy arm was 479 patients, an increase of 53 patients over the 426 patients three months ago. Enrollment in the randomized portion of the DT arm of the trial was 291 patients, versus 265 patients three months ago. Two year follow up on the pivotal 200 randomized Destination Therapy patients will be complete in May 2009. Enrollment in the BTT arm of the trial was 439 patients, compared with 390 patients as of October 26, 2007.

Total enrollment in the Pivotal trial as of January 25 was 918 patients versus 816 three months ago, and an increase of 415 patients over the 503 patients enrolled a year ago.

FINANCIAL HIGHLIGHTS

Thoratec reported revenues of $234.8 million in 2007 com
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Thoratec Presentation at JP Morgan Conference to be Webcast
2. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
3. Thoratec Presentation at Bear Stearns Conference To Be Webcast
4. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
5. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
6. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
7. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
8. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
9. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
10. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
11. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... RIDGE, Tenn., July 24, 2014 -- A novel combination ... the Department of Energy,s Oak Ridge National Laboratory an ... for its unusual physical and electrochemical properties. , ... how oxygen affects the surface of a perovskite manganite, ... behavior. The new avenue to understand surface behavior could ...
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
(Date:7/24/2014)... Research and Markets has announced ... 2014-2018" report to their offering.  ... the in vitro growth of plant or animal cells ... biopharmaceutical production. Cell culture is a crucial step in ... cell culture consumables are necessary for the in vitro ...
(Date:7/24/2014)... San Francisco, CA (PRWEB) July 24, 2014 ... Wednesday to be semi-finalists in Livestrong’s Big C Competition. ... Decisive Health are each headed to the semi-final round. ... in Livestrong’s exclusive three-month accelerator program, complete with mentoring ... country. , As part of the angelMD commitment ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... Researcher Appreciation Event ... ... PHOENIX, Oct. 3 ThirdBiotech Inc., http://www.thirdbiotech.com, a biotechnology incubator ... Appreciation Event to be held on Thursday, October 23rd, 2008,between noon and ...
... http://www.amdl.com ),AMDL, Inc. (Amex: ADL ), a leading ... the US, today announced that the,Company will present at ... on Tuesday, October 7, 2008 at 10:30 a.m. ET. ... York Hotel in the Morosco Room., The Maxim ...
... Support R&D Efforts and Clinical Trials Advancing,the ... Oct. 3 Micromet, Inc. (Nasdaq:,MITI) ("Micromet" ... proprietary antibodies for the treatment of cancer, ... has closed its previously,announced $40 million private ...
Cached Biology Technology:First Annual Arizona Biotech Day Announced for October 23rd 2008 2First Annual Arizona Biotech Day Announced for October 23rd 2008 3AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 2AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 3Micromet Closes $40 Million Private Equity Placement 2Micromet Closes $40 Million Private Equity Placement 3Micromet Closes $40 Million Private Equity Placement 4
(Date:7/25/2014)... is a complex congenital central nervous system disease ... the neural tubes during the embryonic phase. Many ... fecal incontinence and neurocognitive retardation. Such problems decrease ... life. Researchers at Ankara Physical Medicine and Rehabilitation ... performance in children with SB, using the Pediatric ...
(Date:7/25/2014)... girls reach puberty is influenced by ,imprinted genes,a subset of ... gene. This is the first evidence that imprinted genes ... of this study were published today in the journal ... menarche, is a marker for the timing of puberty in ... varies between girls, is an inherited trait, and is linked ...
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... European College of Neuropsychopharmacology (ECNP) is pleased to ... 2009 ECNP Neuropsychopharmacology Award in Basic Science Research ... into the neurochemical basis of substance addiction. ... in the field of neuropsychopharmacology and its closely ...
... Researchers have made significant advances in the treatment of metastatic ... treat successfully once it has started to spread according ... congress, ECCO 15 ESMO 34 [1], in Berlin on ... seen rapid and dramatic shrinking of metastatic tumours in patients ...
... research team at the National Institute of Standards and ... possible cancer therapy has uncovered a delicate balancing act ... says they should be. Just like individuals in a ... because they get close together, but not too close. ...
Cached Biology News:Trial of new treatment for advanced melanoma shows rapid shrinking of tumors 2Trial of new treatment for advanced melanoma shows rapid shrinking of tumors 3Therapeutic nanoparticles give new meaning to sugar-coating medicine 2
... 75 x ... recommended for immunohistochemistry of paraffin-embedded sections, ... at one end, markings ... normal procedures, precleaned, ...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Donor feline serum and plasma...
Request Info...
Biology Products: